Loading...

Purified anti-human CD3 Antibody

Pricing & Availability
Clone
OKT3 (See other available formats)
Regulatory Status
RUO
Workshop
HCDM listed
Other Names
T3, CD3ε
Isotype
Mouse IgG2a, κ
Ave. Rating
Submit a Review
Product Citations
publications
OKT3_Purified_053107
Human peripheral blood lymphocytes stained with purified OKT3, followed by anti-mouse IgGs-FITC
  • OKT3_Purified_053107
    Human peripheral blood lymphocytes stained with purified OKT3, followed by anti-mouse IgGs-FITC
Compare all formats
Cat # Size Price Quantity Check Availability Save
317301 25 µg 24€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
317302 100 µg 44€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
Description

CD3ε is a 20 kD chain of the CD3/T cell receptor (TCR) complex, which is composed of two CD3ε, one CD3γ, one CD3δ, one CD3ζ (CD247), and a T cell receptor (α/β or γ/δ) heterodimer. It is found on all mature T lymphocytes, NK T cells, and some thymocytes. CD3, also known as T3, is a member of the immunoglobulin superfamily that plays a role in antigen recognition, signal transduction, and T cell activation.

Product Details
Technical data sheet

Product Details

Verified Reactivity
Human
Antibody Type
Monoclonal
Host Species
Mouse
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation
The antibody was purified by affinity chromatography.
Concentration
0.5 mg/ml
Storage & Handling
The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

FC - Quality tested
IHC-F - Reported in the literature, not verified in house
Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤0.25 µg per million cells in 100 µl volume. It is recommended that the reagent be titrated for optimal performance for each application.

Application Notes

The OKT3 monoclonal antibody reacts with an epitope on the epsilon-subunit within the human CD3 complex.

Clone OKT3 can block the binding of clones SK7 and UCHT1.4 The OKT3 antibody is able to induce T cell activation. Additional reported applications (for the relevant formats) include: immunohistochemical staining of acetone-fixed frozen sections and activation of T cells. The LEAF™ purified antibody (Endotoxin <0.1 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for functional assays (Cat. No. 317304). For highly sensitive assays, we recommend Ultra-LEAF™ purified antibody (Cat. No. 317326) with a lower endotoxin limit than standard LEAF™ purified antibodies (Endotoxin <0.01 EU/µg).

Application References

(PubMed link indicates BioLegend citation)
  1. Schlossman S, et al. Eds. 1995. Leucocyte Typing V. Oxford University Press. New York.
  2. Knapp W. 1989. Leucocyte Typing IV. Oxford University Press New York.
  3. Barclay N, et al. 1997. The Leucocyte Antigen Facts Book. Academic Press Inc. San Diego.
  4. Li B, et al. 2005. Immunology 116:487.
  5. Jeong HY, et al. 2008. J. Leuckocyte Biol. 83:755. PubMed
  6. Alter G, et al. 2008. J. Virol. 82:9668. PubMed
  7. Manevich-Mendelson E, et al. 2009. Blood 114:2344. PubMed
  8. Pinto JP, et al. 2010. Immunology. 130:217. PubMed
  9. Biggs MJ, et al. 2011. J. R. Soc. Interface. 8:1462. PubMed
Product Citations
  1. Hawley KM, et al. 2022. Proc Natl Acad Sci U S A. 119:e2209044119. PubMed
  2. Sun X, et al. 2023. Cell Death Dis. 14:242. PubMed
  3. Meadows AM, et al. 2023. iScience. 26:106578. PubMed
  4. Eberhardt F, et al. 2023. Int J Mol Med. 52:. PubMed
  5. Chen, Y. L., Yousif, A., et al. 2025. Cancer Immunol Res. 13(11),1829-1844. PubMed
  6. Mammadli M, et al. 2021. Clin Transl Med. 11:e625. PubMed
  7. Kim SJ, et al. 2020. J Biol Chem. 296:100108. PubMed
  8. Saito T, et al. 2022. ACS Chem Biol. 17:217. PubMed
  9. Deepak HB, et al. 2022. Indian J Pharmacol. 54:183. PubMed
  10. Kim HS, et al. 2023. Bioact Mater. 21:241. PubMed
  11. Onnis A, et al. 2023. J Exp Med. 220: . PubMed
  12. Mohamed H, et al. 2023. Biomedicines. 11: . PubMed
  13. Davé E, et al. 2023. MAbs. 15:2160229. PubMed
  14. Mousset CM, et al. 2018. Oncoimmunology. 7:e1488565. PubMed
  15. Jeong H, et al. 2008. J Leukoc Biol. 83:755. PubMed
  16. Biggs M, et al. 2011. J R Soc Interface. 1.348611111. PubMed
  17. Blas-Rus N, et al. 2016. Nat Commun. 7: 11389. PubMed
  18. Li G, et al. 2021. Oncoimmunology. 10:1983306. PubMed
  19. Weinhage T, et al. 2020. J Immunol. 205:56. PubMed
  20. Berkson JD, et al. 2020. Immunohorizons. 4:14. PubMed
  21. Mehta N, et al. 2020. Sci Rep. 10:15171. PubMed
  22. Alcántara‐Hernández M et al. 2017. Immunity. 47(6):1037-1050 . PubMed
  23. Barzilai S, et al. 2017. Cell Rep. 18(3):685-699. PubMed
  24. Bae EA, et al. 2018. Cancer Res. 78:5315. PubMed
  25. Liang J, et al. 2017. Nat Commun. 8:15732. PubMed
  26. Fronik P, et al. 2021. J Med Chem. 64:12132. PubMed
  27. Amiad-Pavlov D, et al. 2021. Sci Adv. 7: . PubMed
  28. Ghosh S, et al. 2020. Cell Reports. 30(10):3434-3447. PubMed
  29. Willing A, et al. 2018. J Immunol. 200:974. PubMed
  30. Bluhm J, et al. 2018. Mol Ther. 26:1906. PubMed
  31. Yarzabek B et al. 2018. eLife. 7 pii: e34961. PubMed
  32. Lang C, Wang J, and Chen L 2017. Exp Cell Res.. 10.1016/j.yexcr.2017.09.030. PubMed
  33. Willimsky G, et al. 2021. Elife. 10:. PubMed
  34. Nissim L et al. 2017. Cell. 171(5):1138-1150 . PubMed
  35. García–Ortiz A, et al. 2017. PLoS Biol. 15:e2000653. PubMed
  36. Kujawski M, et al. 2019. BMC Cancer. 1.404166667. PubMed
  37. Mann ER, et al. 2020. Sci Immunol. :5. PubMed
  38. Nathan A, et al. 2021. Cell. 184(17):4401-4413.e10. PubMed
  39. Kaufmann M, et al. 2021. Med. 2(3):296-312.e8. PubMed
  40. Dilchert J, et al. 2022. Antibodies (Basel). 11:. PubMed
  41. Alcántara-Hernández M, et al. 2021. Nat Protoc. 16:4855. PubMed
  42. Holbrook AK, et al. 2019. Physiol Rep. 7:e14234. PubMed
  43. Winkler M, et al. 2017. PLoS One.. 10.1371/journal.pone.0182427. PubMed
  44. Fu Z, et al. 2021. Acta Pharm Sin B. 11:3925. PubMed
  45. Wilson AS, et al. 2022. Nat Commun. 13:528. PubMed
  46. Jilg N, et al. 2020. J Infect Dis. 222:1837. PubMed
  47. Xiong Y, et al. 2019. J Immunol. 203:3023. PubMed
  48. Kessel C, et al. 2017. Arthritis Rheumatol. 69:1480. PubMed
  49. Hu X, et al. 2021. British Journal of Pharmacology. 178(6):1445-1458. PubMed
  50. Li L, et al. 2020. J Transl Med. 18:363. PubMed
  51. Bertino P, et al. 2019. Oncoimmunology. 8:1601482. PubMed
  52. Li H, et al. 2020. Front Immunol. 11:1777. PubMed
  53. Broos K, et al. 2019. Cancers (Basel). 11. PubMed
  54. Zhao R, et al. 2018. Oncoimmunology. 8:e1509173. PubMed
  55. Hsu CY, et al. 2020. Frontiers in Immunology. 11:574839. PubMed
  56. Kim G, et al. 2021. J Infect Dis. 224:1861. PubMed
  57. , et al. 2021. Eur J Immunol. 51:2708. PubMed
  58. Walk J, et al. 2020. Front Immunol. 2.405555556. PubMed
  59. Johnston HE, et al. 2018. Mol Cell Proteomics. 1.247222222. PubMed
  60. Thomi R, et al. 2017. Br J Dermatol.. 10.1111/bjd.15458. PubMed
  61. Herati RS, et al. 2021. Cell Reports Medicine. 2(5):100262. PubMed
  62. Ito T, et al. 2021. Commun Biol. 4:694. PubMed
  63. Gurusamy M, et al. 2021. Nat Commun. 12:6798. PubMed
  64. Zuñiga J, et al. 2020. Int J Infect Dis. 94:4. PubMed
  65. Wang Q, et al. 2020. J Immunother Cancer. 8:. PubMed
  66. Glud EN, et al. 2022. Br J Cancer. Online ahead of print. PubMed
  67. Mayer KE, et al. 2019. Theranostics. 4.548611111. PubMed
  68. Tripathi T, et al. 2019. Immunohorizons. 0.201388889. PubMed
  69. Alter G, et al. 2008. J Virol. 82:9668. PubMed
  70. Pinto J, et al. 2010. Immunology. 130:217. PubMed
  71. Auladell M, et al. 2019. Clin Transl Immunology. 8:e01090. PubMed
  72. Seo N, et al. 2018. Nat Commun. 9:435. PubMed
  73. Qiu H, et al. 2017. Exp Cell Res.. 10.1016/j.yexcr.2017.08.036. PubMed
  74. Guo J, et al. 2022. J Immunother Cancer. 10:. PubMed
  75. Wiedeman AE, et al. 2020. J Clin Invest. 130:480. PubMed
  76. Rivera-Cruz CM, et al. 2022. Cytotherapy. Online ahead of print. PubMed
  77. Jin Y, et al. 2017. Int Immunopharmacol. . 10.1016/j.intimp.2017.10.009. PubMed
  78. Schoknecht T, et al. 2017. J Leukoc Biol. 101:589. PubMed
  79. Escudero–Pérez B, et al. 2019. JCI Insight. 4:e126070. PubMed
  80. Park S, et al. 2020. Biosens Bioelectron. 112389:165. PubMed
  81. Henrick BM, et al. 2021. Cell. . PubMed
  82. Zavidij O, et al. 2020. Nat Cancer. 0.384027778. PubMed
  83. Lee YS, et al. 2021. J Immunother Cancer. 9:. PubMed
  84. Bacot SM, et al. 2020. Int J Mol Sci. 21:. PubMed
  85. Hirama T, et al. 2021. JCI Insight. 6:. PubMed
  86. Levin SD, et al. 2020. Front Immunol. 10:3086. PubMed
  87. Manevich-Mendelson E, et al. 2009. Blood. 114:2344. PubMed
  88. Caielli S, et al. 2019. Nat Med. 25:75. PubMed
  89. Ardain A, et al. 2019. Nature. 570:528. PubMed
  90. Horn LA, et al. 2017. Oncotarget. 8:57964. PubMed
  91. Singh AK, et al. 2017. Front Immunol. 0.513888889. PubMed
  92. Carriche GM, et al. 2021. J Allergy Clin Immunol. 147:335. PubMed
  93. Pan Y, et al. 2021. Br J Pharmacol. 178:4907. PubMed
  94. Pawlak EN, et al. 2018. Retrovirology. 15:6. PubMed
  95. Meng Q, et al. 2018. Sci Rep. 8:17079. PubMed
  96. Boutboul D, et al. 2018. J Clin Invest. 128:3071. PubMed
  97. Chevalier MF, et al. 2017. J Clin Invest. 127:2916. PubMed
  98. Moosmann C, et al. 2022. STAR Protoc. 3:101031. PubMed
  99. Cassioli C, et al. 2021. Front Cell Dev Biol. 9:673446. PubMed
  100. Müller TR, et al. 2021. Cell Rep Med. 2:100374. PubMed
  101. Benabdallah B, et al. 2019. Front Immunol. 10:2580. PubMed
  102. Sneddon S, et al. 2020. Oncoimmunology. 9:1684713. PubMed
  103. Garcia de Moura R, et al. 2021. Front Immunol. 12:632667. PubMed
  104. Naranbhai V, et al. 2022. Cell. . PubMed
  105. Yang J, et al. 2020. Nat Commun. 11:4402. PubMed
  106. Crome SQ, et al. 2017. Nat Med. 1.213888889. PubMed
  107. Hashimoto M, et al. 2017. Int J Inflam. 2017:1324735. PubMed
  108. Siegers GM, et al. 2020. Front Immunol. 1.352083333. PubMed
  109. Chevrier S, et al. 2021. Cell Reports Medicine. 2(1):100166. PubMed
  110. Srivastava S, et al. 2020. Cancer Cell. 39(2):193-208.e10. PubMed
  111. He Y, et al. 2021. eLife. 10:00. PubMed
  112. Malenica I, et al. 2021. Nat Commun. 12:5209. PubMed
  113. Yin Y, et al. 2017. J Allergy Clin Immunol. 139:1701. PubMed
  114. Akhand SS, et al. 2020. Cancer Immunol Res. 8:1542. PubMed
  115. Liu Z, et al. 2017. Oncotarget. 8:53518. PubMed
  116. Terzuoli E, et al. 2019. Cancers (Basel). 1.821527778. PubMed
  117. Welch JL, et al. 2020. FEBS Lett. 594:695. PubMed
  118. Chiou SH, et al. 2021. Immunity. 54:586. PubMed
  119. Shalata W, et al. 2021. Cancers (Basel). 13: . PubMed
  120. Leylek R, et al. 2020. Cell Rep. 32:108180. PubMed
  121. Dutertre CA, et al. 2020. Immunity. 51(3):573-589.e8.. PubMed
RRID
AB_571926 (BioLegend Cat. No. 317301)
AB_571927 (BioLegend Cat. No. 317302)

Antigen Details

Structure
Ig superfamily, the subunits CD3γ, CD3δ, CD3ζ (CD247) and TCR (α/β or γ/δ) form the CD3/TCR complex, 20 kD
Distribution

Mature T and NK T cells, thymocyte differentiation

Function
Antigen recognition, signal transduction, T cell activation
Ligand/Receptor
Peptide antigen bound to MHC
Cell Type
NKT cells, T cells, Thymocytes, Tregs
Biology Area
Immunology
Molecular Family
CD Molecules
Antigen References
  1. Barclay N, et al. 1993. The Leucocyte FactsBook. Academic Press. San Diego.
  2. Beverly P, et al. 1981. Eur. J. Immunol. 11:329.
  3. Lanier L, et al. 1986. J. Immunol. 137:2501.
Gene ID
916 View all products for this Gene ID
UniProt
View information about CD3 on UniProt.org

Related FAQs

There are no FAQs for this product.
Go To Top Version: 2    Revision Date: 06.12.2013

For Research Use Only. Not for diagnostic or therapeutic use.

 

This product is supplied subject to the terms and conditions, including the limited license, located at www.biolegend.com/terms) ("Terms") and may be used only as provided in the Terms. Without limiting the foregoing, BioLegend products may not be used for any Commercial Purpose as defined in the Terms, resold in any form, used in manufacturing, or reverse engineered, sequenced, or otherwise studied or used to learn its design or composition without express written approval of BioLegend. Regardless of the information given in this document, user is solely responsible for determining any license requirements necessary for user’s intended use and assumes all risk and liability arising from use of the product. BioLegend is not responsible for patent infringement or any other risks or liabilities whatsoever resulting from the use of its products.

 

BioLegend, the BioLegend logo, and all other trademarks are property of BioLegend, Inc. or their respective owners, and all rights are reserved.

 

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

ProductsHere
Login / Register
Remember me
Forgot your password? Reset password?
Create an Account